Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markolf Hanefeld

Showing results (31-40 of 121) with videos related to

Pageof 13
Sort By:
Cardiovascular Diabetology|May 21, 2017
The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mLMarkolf Hanefeld, Louise Traylor, Ling Gao, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 22, 2020
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 UpdateMarkolf Hanefeld, Holger Fleischmann, Thorsten Siegmund, et al.
SAGE Open Medical Case Reports|February 6, 2019
Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case reportAhmad Haider, Karim Haider, Farid Saad, et al.
Journal of Diabetes Science and Technology|June 2, 2010
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazoneAndreas Pfützner, Thomas Schöndorf, Markolf Hanefeld, et al.
Herz|June 14, 2006
[Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy]Markolf Hanefeld, Wolfgang Metzler, Carsta Köhler, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 11, 2016
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsMarkolf Hanefeld, Louis Monnier, Oliver Schnell, et al.
Diabetes Technology & Therapeutics|November 16, 2013
Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experienceMarkolf Hanefeld, Holger Fleischmann, Guido Schiffhorst, et al.
Diabetes Care|June 29, 2005
Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et alMarkolf Hanefeld, Robert G Josse, Jean-Louis Chiasson
Cardiovascular Research|October 24, 2002
Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetesTheodora Temelkova-Kurktschiev, Carsta Koehler, Elena Henkel, et al.
Diabetes Research and Clinical Practice|November 10, 2006
Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjectsPeter E H Schwarz, Stefan R Bornstein, Markolf Hanefeld
Pageof 13

Showing results (31-40 of 121) with videos related to

Sort By:
Pageof 13
Cardiovascular Diabetology|May 21, 2017
The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mLMarkolf Hanefeld, Louise Traylor, Ling Gao, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 22, 2020
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 UpdateMarkolf Hanefeld, Holger Fleischmann, Thorsten Siegmund, et al.
SAGE Open Medical Case Reports|February 6, 2019
Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case reportAhmad Haider, Karim Haider, Farid Saad, et al.
Journal of Diabetes Science and Technology|June 2, 2010
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazoneAndreas Pfützner, Thomas Schöndorf, Markolf Hanefeld, et al.
Herz|June 14, 2006
[Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy]Markolf Hanefeld, Wolfgang Metzler, Carsta Köhler, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 11, 2016
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsMarkolf Hanefeld, Louis Monnier, Oliver Schnell, et al.
Diabetes Technology & Therapeutics|November 16, 2013
Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experienceMarkolf Hanefeld, Holger Fleischmann, Guido Schiffhorst, et al.
Diabetes Care|June 29, 2005
Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et alMarkolf Hanefeld, Robert G Josse, Jean-Louis Chiasson
Cardiovascular Research|October 24, 2002
Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetesTheodora Temelkova-Kurktschiev, Carsta Koehler, Elena Henkel, et al.
Diabetes Research and Clinical Practice|November 10, 2006
Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjectsPeter E H Schwarz, Stefan R Bornstein, Markolf Hanefeld
Pageof 13